SCHEMBL24423925

SCHEMBL24423925

CC(C)(C)OC(=O)NCc1nccnc1C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1H O95180 1/20 0.43
CACNA1B Q00975 1/20 0.43
CACNA1C Q13936 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.41
LMNA P02545 2/20 0.39
KDM4E B2RXH2 2/20 0.39
NAMPT P43490 1/20 0.39
KDM4A O75164 1/20 0.39
MAPKAPK2 P49137 3/20 0.37
POLB P06746 2/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
SSTR4 P31391 1/20 0.36
PRMT5 O14744 1/20 0.36
WDR77 Q9BQA1 1/20 0.36
ATR Q13535 1/20 0.36
GFER P55789 1/20 0.36
STK17B O94768 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19782553 0.81 ATR (0.47) L3MBTL1LMNAKDM4ENAMPTKDM4A
SCHEMBL18764702 0.76 NAMPT (0.46) L3MBTL1LMNAKDM4ENAMPTKDM4A
SCHEMBL20839513 0.76 ATR (0.42) LMNANAMPTPOLBCA1CA2
SCHEMBL30890544 0.74 CHRM2 (0.47) L3MBTL1KDM4ENAMPTKDM4AMAPKAPK2
SCHEMBL1631864 0.74 ADORA2A (0.48) L3MBTL1NAMPTKDM4ASSTR4
SCHEMBL31438501 0.74 L3MBTL1 (0.41) CACNA1HCACNA1BCACNA1CL3MBTL1LMNA
SCHEMBL21455353 0.74 ATR (0.44) L3MBTL1LMNANAMPTKDM4AMAPKAPK2
SCHEMBL30564617 0.74 L3MBTL1 (0.41) CACNA1HCACNA1BCACNA1CL3MBTL1LMNA
SCHEMBL20520904 0.73 CACNA1H (0.45) CACNA1HCACNA1BCACNA1CL3MBTL1LMNA
SCHEMBL1631862 0.73 NAMPT (0.46) L3MBTL1LMNAKDM4ENAMPTKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 US disclosed
WO-2022099144-A1 ΡΡΑRγ MODULATORS AND METHODS OF USE Eisai R&D Mangement Co., Ltd. (JP) 2022-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE PPARG, PPARA, PPARD CACNA1H 3436/4885CACNA1B 2947/4885CACNA1C 3550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.